For aCD20-MS patients, a small increase was observed in the number of IFNγ+-secreting T-cells (from 77.4% before to 91.7% after), with almost full positivity before and after re-exposure for IL-2+ and IFNγ+/IL-2+. This evidence concerns the gene IL2 and myeloid sarcoma.